Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 844-other-myeloproliferative-disorders-or-poorly-differentiated-neoplastic-diagnoses-with-cc
    Ask Trek AI about this page

    Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with CC: Inpatient Reimbursement Overview

    DRG 844 groups admissions for other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with a Complication or Comorbidity, encompassing hematologic and oncologic clinical management that increases inpatient resource use. Proper coding and documentation matter for inpatient reimbursement because the Complication or Comorbidity status affects the Diagnosis-Related Group assignment and resulting Medicare payment.

    Customize your policy alerts

    Sign up for drg 844 policy alerts

    Get alerted when payer policies referencing 844 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 844 Overview

    DRG 844 covers hospital admissions for other myeloproliferative disorders or poorly differentiated neoplastic diagnoses when a Complication or Comorbidity is present. These cases typically involve hematology and oncology evaluation, often requiring transfusions, cytoreductive therapy, or management of disease-related complications. This Diagnosis-Related Group matters for Medicare payment because the presence of a Complication or Comorbidity adjusts relative resource use and hospital reimbursement under inpatient prospective payment. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and the associated payment weight.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute intervention trials assessing targeted cytoreductive strategies or supportive care protocols in hospitalized patients with symptomatic myeloproliferative disorders (MPNs) or poorly differentiated hematologic neoplasms: these studies enroll inpatients presenting with complications such as hyperviscosity, severe thrombocytosis, symptomatic splenomegaly, bleeding, or marrow failure to compare rapid-acting interventions (e.g., urgent cytoreduction approaches, transfusion algorithms, or pheresis protocols) versus standard inpatient management. The focus is on short-term clinical stabilization, complication resolution, and avoiding ICU-level care, and findings are directly relevant to hospitals and payers because they influence length of stay, resource utilization, and need for high-cost supportive therapies.
    • Comparative effectiveness and sequencing studies of disease-modifying therapies for chronic or refractory myeloproliferative disorders transitioning from inpatient to outpatient care: these trials enroll patients hospitalized for disease exacerbation or complications who require initiation, change, or escalation of systemic therapy, comparing different therapeutic classes or initiation timing strategies to evaluate relapse prevention, readmission rates, and adverse-event profiles over months to a year. Results inform clinicians and payers about which treatment approaches reduce rehospitalizations, total episode costs, and long-term complication burden in this heterogeneous population with varying risk profiles and comorbidities.
    • Post-discharge outcomes and care-coordination research focusing on readmission prevention, symptom monitoring, and palliative integration for patients with poorly differentiated hematologic neoplasms or advanced MPNs: these observational or interventional studies test discharge bundles, remote monitoring, multidisciplinary follow-up, or early palliative care referral to track quality-of-life, unplanned readmissions, end-of-life care patterns, and utilization metrics. Such research targets a high-risk cohort with complex needs; its findings are important for providers and payers seeking to improve care transitions, reduce preventable readmissions, and align resource use with patient-centered outcomes.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.